Precision Clinical Medicine最新文献

Single-cell transcriptomic profiling reveals distinct tumor microenvironments in HPV-associated penile squamous cell carcinoma. 单细胞转录组分析揭示了hpv相关阴茎鳞状细胞癌中不同的肿瘤微环境。

IF 5 4区医学

Precision Clinical Medicine Pub Date : 2025-09-08 eCollection Date: 2025-09-01 DOI: 10.1093/pcmedi/pbaf013

Lianbang Zhu, Deyun Shen, Jiahao Zhou, Chen Cheng, Zhiyao Xu, Yong Liang, Wen Pan, Tao Tao

{"title":"Single-cell transcriptomic profiling reveals distinct tumor microenvironments in HPV-associated penile squamous cell carcinoma.","authors":"Lianbang Zhu, Deyun Shen, Jiahao Zhou, Chen Cheng, Zhiyao Xu, Yong Liang, Wen Pan, Tao Tao","doi":"10.1093/pcmedi/pbaf013","DOIUrl":"10.1093/pcmedi/pbaf013","url":null,"abstract":"Background: Penile squamous cell carcinoma (PSCC) is a rare yet potentially lethal malignancy, often resulting in devastating disfigurement, with a 5-year survival rate of only ∼50%. Human papillomavirus (HPV) infection is implicated in approximately half of PSCC cases and is associated with improved clinical outcomes; however, the underlying mechanisms remain poorly understood.Methods: To elucidate HPV-associated differences in the tumor microenvironment, we performed single-cell RNA sequencing on tumors from 11 treatment-naïve PSCC patients, analyzing a total of 52 980 single cells. Unsupervised clustering identified 49 distinct cellular clusters across immune and stromal compartments.Results: HPV-positive tumors exhibited an increased abundance of mast cells and a reduction in the proliferative macrophages subpopulation compared to HPV-negative tumors. Notably, CD8+ T cells in HPV-positive PSCC expressed lower levels of immune checkpoint molecules, suggesting a less exhausted immune state. Conversely, TIGIT and its ligands were significantly enriched in HPV-negative tumors, potentially fostering an immunosuppressive niche.Conclusion: Collectively, our study delineates the single-cell landscape of PSCC and highlights distinct tumor microenvironment remodeling associated with HPV status, suggesting that the reduced immunosuppression in HPV-positive tumors may underlie their more favorable prognosis.","PeriodicalId":33608,"journal":{"name":"Precision Clinical Medicine","volume":"8 3","pages":"pbaf013"},"PeriodicalIF":5.0,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12421235/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145041681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bile acid metabolism and hcepatocellular carcinoma: mechanisms of drug resistance and intervention strategies. 胆汁酸代谢与肝细胞癌：耐药机制及干预策略。

IF 5 4区医学

Precision Clinical Medicine Pub Date : 2025-08-20 eCollection Date: 2025-09-01 DOI: 10.1093/pcmedi/pbaf020

Yan Lu, Xiaochen Feng, Zhijie Wang, Minghao Zou, Zheqi Xu, Qianjia Liu, Wenjin Chen, Jin Ding, Hui Liu

{"title":"Bile acid metabolism and hcepatocellular carcinoma: mechanisms of drug resistance and intervention strategies.","authors":"Yan Lu, Xiaochen Feng, Zhijie Wang, Minghao Zou, Zheqi Xu, Qianjia Liu, Wenjin Chen, Jin Ding, Hui Liu","doi":"10.1093/pcmedi/pbaf020","DOIUrl":"10.1093/pcmedi/pbaf020","url":null,"abstract":"Hepatocellular carcinoma (HCC) is the predominant malignant liver tumor, characterized by high morbidity, mortality, and rapid progression, and it ranks among the leading causes of cancer-related fatalities worldwide. Its treatment is facing the severe challenge of resistance to targeted drugs and immunotherapy. Bile acids (BAs) are products of cholesterol metabolism, that not only regulate lipid digestion and absorption, but also influence the development of HCC by modulating inflammation and metabolism. Dysregulation of BA metabolism is closely linked to resistance against targeted therapies and immunotherapies. BAs reduce the efficacy of targeted drugs by influencing enzymes involved in drug metabolism and drug efflux transporters, moreover, BAs also lead to immunotherapeutic resistance by regulating the formation of the immunosuppressive tumor microenvironment. Therefore, regulating BA metabolism has the potential to overcome drug resistance of targeted therapy and immunotherapy, which could be a promising treatment strategy. This review not only summarizes the roles of BA metabolism in HCC development and drug resistance, but also further explores the rationality and necessity of targeting BAs to enhance the survival of HCC patients.","PeriodicalId":33608,"journal":{"name":"Precision Clinical Medicine","volume":"8 3","pages":"pbaf020"},"PeriodicalIF":5.0,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12448427/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145114378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Molecular mechanisms and genetic features of cholangiocarcinoma: implications for targeted therapeutic strategies. 胆管癌的分子机制和遗传特征：对靶向治疗策略的影响。

IF 5 4区医学

Precision Clinical Medicine Pub Date : 2025-08-20 eCollection Date: 2025-09-01 DOI: 10.1093/pcmedi/pbaf021

Xiao Lu, Shoujia Xu, Zhe Deng, Min-Jun Wang, Fei Chen

{"title":"Molecular mechanisms and genetic features of cholangiocarcinoma: implications for targeted therapeutic strategies.","authors":"Xiao Lu, Shoujia Xu, Zhe Deng, Min-Jun Wang, Fei Chen","doi":"10.1093/pcmedi/pbaf021","DOIUrl":"10.1093/pcmedi/pbaf021","url":null,"abstract":"Cholangiocarcinoma (CCA) is a biologically diverse and highly aggressive cancer that arises from the biliary epithelium. It is typically divided into intrahepatic, perihilar, and distal types, each with distinct clinical behavior, genetic alterations, and therapeutic responses. Worldwide, the global incidence of CCA has risen steadily, accounting for nearly 15% of liver cancers and ∼3% of all gastrointestinal malignancies. CCA often presents at an advanced stage due to its silent onset and shows poor responsiveness to conventional chemotherapy, resulting in high mortality, accounting for ∼2% of cancer-related deaths worldwide. Risk factors include parasitic infections like liver flukes and chronic biliary diseases such as cholelithiasis and primary sclerosing cholangitis, although most cases have unknown origins. While early-stage patients may benefit from surgical resection or liver transplantation, these options are often not viable in advanced disease due to high relapse rates. In cases of unresectable or metastatic CCA, treatment remains difficult due to resistance and a lack of effective targeted therapies. This review systematically integrates the genomic, epigenetic, and signaling network mechanisms underlying CCA with their translational implications, providing a critical synthesis of the rapidly evolving field of targeted therapies, including recently approved Food and Drug Administration treatments and emerging novel agents. We specifically emphasize the key mechanisms of therapeutic resistance and corresponding strategies to overcome them, present an updated evaluation of vulnerabilities across distinct molecular subgroups, and explore the major challenges and future trajectories for advancing biomarker-driven precision medicine in CCA, thereby offering a forward-looking and clinically relevant perspective.","PeriodicalId":33608,"journal":{"name":"Precision Clinical Medicine","volume":"8 3","pages":"pbaf021"},"PeriodicalIF":5.0,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12448423/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145114337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Genetic architecture of hypertrophic cardiomyopathy in individuals of Chinese and United Kingdom ancestry. 中国和英国血统肥厚性心肌病个体的遗传结构。

IF 5 4区医学

Precision Clinical Medicine Pub Date : 2025-07-24 eCollection Date: 2025-09-01 DOI: 10.1093/pcmedi/pbaf019

Jie Wang, Dominic Russ, Yongsan Yang, Lutong Pu, Mengdi Yu, Jinquan Zhang, Jiajun Guo, Yuanwei Xu, Ke Wan, Heng Xu, Yuchi Han, Georgios V Gkoutos, Yucheng Chen

{"title":"Genetic architecture of hypertrophic cardiomyopathy in individuals of Chinese and United Kingdom ancestry.","authors":"Jie Wang, Dominic Russ, Yongsan Yang, Lutong Pu, Mengdi Yu, Jinquan Zhang, Jiajun Guo, Yuanwei Xu, Ke Wan, Heng Xu, Yuchi Han, Georgios V Gkoutos, Yucheng Chen","doi":"10.1093/pcmedi/pbaf019","DOIUrl":"10.1093/pcmedi/pbaf019","url":null,"abstract":"Background: No studies have explored the genetic differences between the Chinese and other ethnic hypertrophic cardiomyopathy (HCM) populations.Methods: This cross-sectional study included Chinese patients (n = 593) with HCM and controls (n = 491) who underwent whole-exome sequencing. Rare variants in 16 validated HCM genes were assessed and compared with a United Kingdom HCM cohort (n = 1 232) and controls (n = 344 745).Results: Chinese HCM patients have a higher proportion of rare variants (52.8% vs 13.6%, P < 0.001) but have a similar proportion of pathogenic (P) or likely pathogenic (LP) variants compared to the UK cohort. In addition, the Chinese cohort had additional associations with the combined thin filament genes (P = 1.29E-9) and myosin light chain genes (P = 4.43E-3). The United Kingdom cohort was significantly associated with MYBPC3 non-truncating variants (P = 2.99E-7). By classifying variants using the tool genebe, the variants of uncertain significance were minimized to 46.8% compared to other tools (63.3% by Intervar; 91.3% by CardioClassifier). Furthermore, we report that c.3624del in MYBPC3 and c.300C > G in TNNT2 account for 2.9% and 1.5% of all Chinese HCM cases, respectively.Conclusion: Our findings suggested that patients of Chinese ancestry with HCM have a higher proportion of rare variants but are less likely to be classified as P/LP variants in HCM genes than those of European origin. The variants of c.3624del in MYBPC3 and c.300C > G in TNNT2 were specific to Chinese individuals and provide important insights into the ethnic differences of HCM genetic architecture.","PeriodicalId":33608,"journal":{"name":"Precision Clinical Medicine","volume":"8 3","pages":"pbaf019"},"PeriodicalIF":5.0,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12375896/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144972151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Glycosylation in kidney diseases. 肾脏疾病中的糖基化。

IF 5 4区医学

Precision Clinical Medicine Pub Date : 2025-07-11 eCollection Date: 2025-09-01 DOI: 10.1093/pcmedi/pbaf017

Yingying Ling, Fei Cai, Tao Su, Yi Zhong, Ling Li, Bo Meng, Guisen Li, Meng Gong, Hao Yang, Xinfang Xie, Zhenyu Sun, Yang Zhao, Fang Liu, Yong Zhang

{"title":"Glycosylation in kidney diseases.","authors":"Yingying Ling, Fei Cai, Tao Su, Yi Zhong, Ling Li, Bo Meng, Guisen Li, Meng Gong, Hao Yang, Xinfang Xie, Zhenyu Sun, Yang Zhao, Fang Liu, Yong Zhang","doi":"10.1093/pcmedi/pbaf017","DOIUrl":"10.1093/pcmedi/pbaf017","url":null,"abstract":"Protein glycosylation is a critical post-translational modification that influences protein folding, localization, stability, and functional interactions by attaching glycans to specific sites. This process is crucial for biological functions of glycoproteins, and aberrant glycosylation can lead to genetic disorders, immune system issues, and multi-organ pathologies. Recent advancements in glycoproteomic technologies have made the study of protein glycosylation a key focus for understanding the pathogenesis of kidney diseases. This review provides a comprehensive overview of protein glycosylation mechanisms, its biological roles, molecular pathways, and significant functions in renal physiology and pathology. It specifically highlights the dynamic changes and regulatory networks associated with aberrant glycosylation in kidney diseases such as immunoglobulin A nephropathy, diabetic kidney disease, autosomal dominant polycystic kidney disease, renal cell carcinoma, and acute kidney injury. It also evaluates the clinical applications of related technologies and biomarkers. Additionally, it discusses the challenges in developing glycosylation-targeted therapeutic strategies. Future research should focus on clarifying cell-specific glycosylation regulatory networks in the kidney, integrating glycobiology with multi-omics approaches, and improving precision diagnostics and treatment for kidney diseases.","PeriodicalId":33608,"journal":{"name":"Precision Clinical Medicine","volume":"8 3","pages":"pbaf017"},"PeriodicalIF":5.0,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12368498/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144972158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A benchmarking study of copy number variation inference methods using single-cell RNA-sequencing data. 使用单细胞rna测序数据的拷贝数变异推断方法的基准研究。

IF 5.1 4区医学

Precision Clinical Medicine Pub Date : 2025-06-04 eCollection Date: 2025-06-01 DOI: 10.1093/pcmedi/pbaf011

Xin Chen, Li Tai Fang, Zhong Chen, Wanqiu Chen, Hongjin Wu, Bin Zhu, Malcolm Moos, Andrew Farmer, Xiaowen Zhang, Wei Xiong, Shusheng Gong, Wendell Jones, Christopher E Mason, Shixiu Wu, Chunlin Xiao, Charles Wang

{"title":"A benchmarking study of copy number variation inference methods using single-cell RNA-sequencing data.","authors":"Xin Chen, Li Tai Fang, Zhong Chen, Wanqiu Chen, Hongjin Wu, Bin Zhu, Malcolm Moos, Andrew Farmer, Xiaowen Zhang, Wei Xiong, Shusheng Gong, Wendell Jones, Christopher E Mason, Shixiu Wu, Chunlin Xiao, Charles Wang","doi":"10.1093/pcmedi/pbaf011","DOIUrl":"10.1093/pcmedi/pbaf011","url":null,"abstract":"Background: Single-cell RNA-sequencing (scRNA-seq) has emerged as a powerful tool for cancer research, enabling in-depth characterization of tumor heterogeneity at the single-cell level. Recently, several scRNA-seq copy number variation (scCNV) inference methods have been developed, expanding the application of scRNA-seq to study genetic heterogeneity in cancer using transcriptomic data. However, the fidelity of these methods has not been investigated systematically.Methods: We benchmarked five commonly used scCNV inference methods: HoneyBADGER, CopyKAT, CaSpER, inferCNV, and sciCNV. We evaluated their performance across four different scRNA-seq platforms using data from our previous multicenter study. We evaluated scCNV performance further using scRNA-seq datasets derived from mixed samples consisting of five human lung adenocarcinoma cell lines and also sequenced tissues from a small cell lung cancer patient and used the data to validate our findings with a clinical scRNA-seq dataset.Results: We found that the sensitivity and specificity of the five scCNV inference methods varied, depending on the selection of reference data, sequencing depth, and read length. CopyKAT and CaSpER outperformed other methods overall, while inferCNV, sciCNV, and CopyKAT performed better than other methods in subclone identification. We found that batch effects significantly affected the performance of subclone identification in mixed datasets in most methods we tested.Conclusion: Our benchmarking study revealed the strengths and weaknesses of each of these scCNV inference methods and provided guidance for selecting the optimal CNV inference method using scRNA-seq data.","PeriodicalId":33608,"journal":{"name":"Precision Clinical Medicine","volume":"8 2","pages":"pbaf011"},"PeriodicalIF":5.1,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12204187/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144529934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The gut virome in association with the bacteriome in gastrointestinal diseases and beyond: roles, mechanisms, and clinical applications. 肠道病毒组与细菌组在胃肠道疾病及其他疾病中的作用、机制和临床应用

IF 5.1 4区医学

Precision Clinical Medicine Pub Date : 2025-05-28 eCollection Date: 2025-06-01 DOI: 10.1093/pcmedi/pbaf010

Zhiyang Feng, Elke Burgermeister, Anna Philips, Tao Zuo, Weijie Wen

引用次数: 0

Risk factors associated with morbidity and unfavorable treatment outcome in drug-resistant pulmonary tuberculosis: a case-control study. 与耐药肺结核发病率和不良治疗结果相关的危险因素：一项病例对照研究

IF 5.1 4区医学

Precision Clinical Medicine Pub Date : 2025-04-18 eCollection Date: 2025-06-01 DOI: 10.1093/pcmedi/pbaf008

Changshu Li, Shufan Liang, Xue Wang, Su Lui, Chengdi Wang

{"title":"Risk factors associated with morbidity and unfavorable treatment outcome in drug-resistant pulmonary tuberculosis: a case-control study.","authors":"Changshu Li, Shufan Liang, Xue Wang, Su Lui, Chengdi Wang","doi":"10.1093/pcmedi/pbaf008","DOIUrl":"10.1093/pcmedi/pbaf008","url":null,"abstract":"Objectives: To investigate the risk factors in patients with drug-resistant tuberculosis (DR-TB) and clinical characteristics related to unfavorable anti-TB treatment outcomes.Methods: A total of 961 pulmonary tuberculosis (TB) patients were included at West China Hospital of Sichuan University from January 2008 to November 2023. We analyzed the differences of clinical characteristics between DR-TB and drug-sensitive tuberculosis (DS-TB), and then compared these features in DR-TB patients with different outcomes. Multivariable logistic regression models were employed to quantify risk factors associated with DR-TB and adverse treatment outcomes.Results: Among 961 pulmonary TB patients, a history of anti-TB treatment [odds ratio (OR), 3.289; 95% confidence interval (CI), 2.359-4.604] and CT-scan cavities (OR, 1.512; 95% CI, 1.052-2.168) increased DR-TB risk. A total of 214 DR-TB patients were followed for a median of 24.5 months. Among them, 116/214 (54.2%) patients achieved favorable outcomes. Prior anti-TB treatment (OR, 1.927; 95% CI, 1.033-3.640), multidrug-resistant tuberculosis (MDR-TB) (OR, 2.558; 95% CI, 1.272-5.252), positive sputum bacteriology (OR, 2.116; 95% CI, 1.100-4.134), and pleural effusion (OR, 2.097; 95% CI, 1.093-4.082) were associated with unfavorable outcomes, while isoniazid-resistant TB patients showed better outcomes (OR, 0.401; 95% CI, 0.181-0.853). The clinical model for unfavorable outcome prediction of DR-TB achieved an area under the curve (AUC) of 0.754 (95% CI, 0.690-0.818).Conclusions: Treatment history of anti-TB not only increases the risk of the emergence of DR-TB, but also potentially leads to treatment failure during re-treatment in DR-TB patients. Drug resistance subtypes, radiological characteristics, and the results of sputum smear or culture may affect the treatment outcome of DR-TB.","PeriodicalId":33608,"journal":{"name":"Precision Clinical Medicine","volume":"8 2","pages":"pbaf008"},"PeriodicalIF":5.1,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12147716/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144259049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Liquid biopsy in head and neck cancer patients: blood, saliva, or both ? 头颈癌患者的液体活检：血液，唾液，还是两者都有？

IF 5.1 4区医学

Precision Clinical Medicine Pub Date : 2025-02-28 eCollection Date: 2025-03-01 DOI: 10.1093/pcmedi/pbaf005

Valentina De Pascale, Federica Ganci, Fabrizio Leone, Valentina Manciocco, Flaminia Campo, Anastasia Mercurio, Alina Catalina Palcau, Claudio Moretti, Frauke Goeman, Sara Donzelli, Giulia Orlandi, Federica Orrù, Renato Covello, Paola Muti, Sabrina Strano, Antonello Vidiri, Raul Pellini, Giovanni Blandino

引用次数: 0

Precision medication based on the evaluation of drug metabolizing enzyme and transporter functions. 基于药物代谢酶和转运体功能评价的精准用药。

IF 5.1 4区医学

Precision Clinical Medicine Pub Date : 2025-02-22 eCollection Date: 2025-03-01 DOI: 10.1093/pcmedi/pbaf004

Yanrong Ma, Jing Mu, Xueyan Gou, Xinan Wu

{"title":"Precision medication based on the evaluation of drug metabolizing enzyme and transporter functions.","authors":"Yanrong Ma, Jing Mu, Xueyan Gou, Xinan Wu","doi":"10.1093/pcmedi/pbaf004","DOIUrl":"10.1093/pcmedi/pbaf004","url":null,"abstract":"Pharmacogenomics, therapeutic drug monitoring, and the assessments of hepatic and renal function have made significant contributions to the advancement of individualized medicine. However, their lack of direct correlation with protein abundance/non-genetic factors, target drug concentration, and drug metabolism/excretion significantly limits their application in precision drug therapy. The primary task of precision medicine is to accurately determine drug dosage, which depends on a precise assessment of the ability to handle drugs in vivo, and drug metabolizing enzymes and transporters are critical determinants of drug disposition in the body. Therefore, accurately evaluating the functions of these enzymes and transporters is key to assessing the capacity to handle drugs and predicting drug concentrations in target organs. Recent advancements in the evaluation of enzyme and transporter functions using exogenous probes and endogenous biomarkers show promise in advancing personalized medicine. This article aims to provide a comprehensive overview of the latest research on markers used for the functional evaluation of drug-metabolizing enzymes and transporters. It also explores the application of marker omics in systematically assessing their functions, thereby laying a foundation for advancing precision pharmacotherapy.","PeriodicalId":33608,"journal":{"name":"Precision Clinical Medicine","volume":"8 1","pages":"pbaf004"},"PeriodicalIF":5.1,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11920622/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143664828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0